FDA Approval Boost J&J’s Spravato 02 Sep 20250 The FDA has approved Johnson & Johnson’s Spravato (esketamine), the first standalone treatment for Treatment Resistant Depression (TRD). Unlike traditional antidepressants, the... Read More
